Lecanemab

Therapeutic indications

Lecanemab is indicated for:

Mild cognitive impairment and mild dementia due to Alzheimer's disease

Population group: only adults (18 years old or older)

Lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer's disease (Early Alzheimer's disease) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes with confirmed amyloid pathology.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Lecanemab is contraindicated in the following cases:

Lactation

Lactation

Patients with bleeding disorders that are not under adequate control

at least one of
Bleeding
Blood coagulation disorder

Cerebral amyloid angiopathy (CAA)

Cerebral amyloid angiopathy

Concomitant antithrombotic medication

Antithrombotic agents

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈